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Purpose: To evaluate the results of transurethral resection (TUR), external beam radiotherapy (EBRT), and 
interstitial radiation (IRT) with iridium-192, using the afterloading technique in patients with muscle invasive 
bladder cancer. 
Methods and Materials: From May 1989 until September 1995,66 patients with primary, solitary muscle invasive 
bladder cancer were treated with TUR, EBRT, and IRT, aiming at bladder preservation. According to the 
protocol, in three patients low-dose EBRT was applied, whereas 63 patients received high-dose EBRT. Imme- 
diately prior to IRT, 42 patients underwent a lymphnode dissection, and in 16 cases a partial cystectomy was 
performed. For IRT, two to five catheters were used and IRT was started within 24 h after surgery. The majority 
of patients received 30 Gy of IRT, with a mean dose rate of 58 Gy/h. In three patients, additional EBRT was 
applied following IRT. Follow-up consisted of regular cystoscopies, mostly done during joint clinics of urologist 
and radiation oncologist, with urine cytology routinely performed. The median follow-up period was 26 months. 
The Kaplan-Meier method was used for the determination of survival rates. 
Results: In seven patients, a bladder relapse developed. The probability of remaining bladder relapse free at 5 
years was 88%. The bladder was preserved in 98% of the surviving patients. Metastases developed in 16 patients, 
and the probability of remaining metastasis free at 5 years was 66%. The cumulative 5-year overall and bladder 
and distant relapse free survival were 48% and 69%, respectively. Acute toxicity was not serious in the majority 
of cases; surgical correction of a persisting vesicocutaneous fistula was necessary in two patients, whereas a 
wound toilet had to be performed in another patient. Serious late toxicity (bladder, RTOG Grade 3) was 
experienced by only one patient. 
Conclusions: Interstitial radiation preceded by TUR and EBRT, in a selected group of patients with muscle 
invasive bladder cancer, yields an excellent bladder tumor control rate with a high probability of bladder 
preservation. Survival was mainly dependent on the development of distant me&stases. Serious acute and late 
toxicity was rare. 0 1997 Elsevier Science Inc. 
Bladder cancer, Interstitial radiation, Bladder preservation. 
INTRODUCTION 
To our knowledge, the idea of interstitial radiotherapy (IRT) 
for tumors by radium was developed in Paris in the first 
decade of the 20th century. Shortly afterwards, reports 
emerged from several centers in Europe and the United 
States of America concerning IRT in bladder cancer by 
permanent implantation of radon seeds (2, 12, 21, 23, 30, 
52) or gold grains (8, 32, 55), or by temporary insertion of 
radium needles (8, 10, 21,24,27,43) or cobalt needles (38), 
or of tantalum wires (5, 38, 51, 55), or iridium wires (35). 
Obviously, the radiation hazard of these methods was a 
serious disadvantage. This problem could be solved by the 
development of an afterloading system using iridium wires, 
which was first described in 1969 (19). To date, the iridium 
afterloading technique is considered standard in IRT in 
bladder cancer (3, 31, 34, 37). 
At the Dr. Daniel den Hoed Cancer Center radium 
needles were introduced in the treatment of bladder can- 
cer in 1951; they were replaced by caesium needles in 
1983, whereas the afterloading iridium wire technique 
was adopted in 1989. Besides the reduction in radiation 
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exposure, this technique offers the opportunity of dose 
optimization to some extent by choosing wires of differ- 
ent activity or by using different application times within 
the implanted volume. Pulsed-dose rate (PDR) brachy- 
therapy using a single iridium source “stepping” 
through a range of dwell positions is a new type of IRT 
simulating a continuous low-dose rate (LDR) treatment 
by a series of fractions (pulses) of short duration with 
time intervals between fractions of 1 h to a few h (7). In 
PDR, optimization of dose distribution is possible by 
dwell time variations (26). 
Table 1. Patient and tumor characteristics 
Number of patients 
Sex 
Male 
Female 
Age 
By regular evaluation of IRT results and exploration of 
the role of several schemes of additional external beam 
radiotherapy (EBRT) and of prognostic factors (44-49), for 
patients with solitary bladder cancer with a limited surface 
diameter (<.5 cm), the following treatment policy was de- 
veloped at our center: Tl tumors: IRT 60 Gy, T2 tumors 
without adverse prognostic factors: EBRT 3 X 3.5 Gy 
followed by IRT 60 Gy, T2 tumors with adverse prognostic 
factors (e.g. poorly differentiated, vascular invasion, ureter 
obstruction), and T3 tumors: EBRT 20 X 2.0 Gy in con- 
junction with IRT 30 Gy. 
Mean 
Range 
Histology 
Transitional cell carcinoma 
Squamous cell carcinoma 
Adenocarcinoma 
Grade 
In this article we present our first experience in afterload- 
ing IRT preceded by EBRT in patients with muscle invasive 
bladder cancer. 
METHODS AND MATERIALS 
Patient population 
From May 1989 until September 1995, 66 patients with 
primary, solitary muscle invasive bladder cancer were 
treated by transurethral resection (TUR), followed by EBRT 
in conjunction with IRT at the Dr. Daniel den Hoed Cancer 
Center (DDHCC). As mentioned above, patients with a 
tumor surface diameter of less than 5 cm were considered 
for this bladder preserving procedure. Other conditions for 
this treatment were the possibility to cover the tumor area 
sufficiently by a one-plane implant and a patient condition 
permitting surgery. In general, the decision concerning final 
treatment following TUR was made after a joint evaluation 
of the patient by the referring urologist and the radiation 
oncologist. Patient and tumor characteristics are shown in 
Table 1. 
3 
4 
Structure 
Papillary 
Solid 
Papillary and solid 
Not given 
Depth of infiltration 
Muscle, superficial 
Muscle, deep 
Muscle, not specified 
Perivesical fat 
T-category* 
T2 
T3a 
T3b 
Site 
Dome 
Right lateral wall 
Left lateral wall 
Posterior wall 
Anterior wall 
Right ureter ostium 
Left ureter ostium 
Bladder neck 
Urographylsonography 
No obstruction 
Unilateral obstruction 
Not performed 
Lymph node staging 
Computer tomography 
Surgery 
Not performed 
* TNM classification 1987, 4th edition. 
The T-category was defined before definitive treatment 
according to the 1987 TNM classification (22). In one 
case, the T2 tumor was multiple. Urography or abdominal 
sonography revealed a normal upper urinary tract in 40 
patients, whereas in 7 patients a unilateral obstruction 
was observed; no information was available in the re- 
maining 19 patients. 
tion. In the remaining 14 patients no information was sought 
on the nodes. 
Treatment 
Lymphnode staging by computer tomography (CT) was 
performed in 51 patients showing no metastases. In one 
case, a lymphnode dissection was carried out during surgery 
for an aneurysm of the abdominal aorta before a decision 
was taken concerning definitive treatment of the bladder 
tumor; no metastases were found on histological examina- 
All patients were first treated by TUR of visible tumor. 
According to our protocol, in three cases 10.5 Gy EBRT 
(3 X 3.5 Gy) was applied immediately prior to IRT, 
whereas 62 patients received 40 Gy EBRT (20 X 2.0 Gy) 3 
to 42 days (median 13) preceding IRT; in one patient an 
additional fraction of 2.0 Gy was given to compensate for 
treatment interruption. The EBRT target area was the true 
pelvis, radiation being given through opposed anterior and 
posterior fields (dose calculation in the midplane) in 63 
66 
50 
16 
67 
36-82 
63 
2 
1 
1 
9 
55 
1 
12 
21 
20 
13 
12 
3 
50 
1 
62 
3 
I 
8 
21 
13 
7 
2 
7 
4 
4 
40 
7 
19 
51 
1 
14 
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Table 2. Partial cystectomy following EBRT, 
pathological T-category 
Pathological T-category 
PTO 
PTX 
pTl(is) 
pT3a 
pT3b 
Total 
No. of patients (%) 
8 (50) 
1 (6) 
1 (6) 
3 (19) 
3 (19) 
16 (100) 
patients; in three cases a CT based multiple field planning 
was used. 
Surgery and insertion of catheters for IRT was performed 
under epidural anesthesia in 62 patients, whereas in 4 pa- 
tients general anesthesia was given. 
A lymphnode dissection of the obturator fossa was per- 
formed immediately before the insertion of the catheters for 
IRT, in 42 patients (38 unilaterally and 4 bilaterally); me- 
tastases were found in 3 of them (7%). It was at the 
discretion of the urologist involved whether a lymphnode 
dissection was to be performed or not. 
To facilitate the positioning of the catheters, in 14 pa- 
tients an excision of the tumor area (partial cystectomy) was 
performed, in 2 of them combined with the reimplantation 
of a ureter and in 1 in combination with a nephrectomy. In 
another two patients a partial cystectomy had to be per- 
formed first, because the tumor process appeared to be too 
large to perform the originally planned procedure. The 
partial cystectomy was preceded by 40 Gy EBRT in 15 
patients and by 10.5 Gy EBRT in 1 patient. The initial 
T-category in this subgroup of patients was T2 in 15 pa- 
tients and T3b in 1 patient. Histological examination 
showed no residual tumor (pTo) (n = S), devitalized tumor 
cells (pTx) (n = l), superficially infiltrating tumor and 
concomitant carcinoma in situ (pTl(is)) (n = l), deep 
muscle infiltrating tumor (pT3a) (n = 3), and tumor infil- 
trating perivesical fat (pT3b) (n = 3). In the latter three 
cases the resection was not radical. In the one T3b patient of 
this group no residual tumor was found after 40 Gy EBRT. 
Table 2 shows the pT-categories. The catheters for IRT 
were inserted at the resection margins after repair of the 
defect. 
In the patients in whom a partial cystectomy was not 
considered necessary, the bladder was opened in the 
midline of the anterior wall, unless the tumor site re- 
quired a paramedian incision, and catheters were inserted 
parallel to each other, l-l .5 cm apart, covering the target 
area, the outer two positioned just outside the area to be 
irradiated. In one patient a second tumor was discovered 
at the time of implantation; after resection it was decided 
to treat this area with IRT also. Because at histopatho- 
logical examination it appeared to be a Tl tumor, data 
concerning management of this second tumor in one 
patient are not included in further analyses. The ends of 
the catheters were threaded through the abdominal wall 
separately at both sides lateral to the incision and before 
the bladder and the abdominal wall were closed, the exact 
length and position of the iridium wires that were to be 
used were defined. 
After completion of the operation orthogonal radiographs 
were made of the implanted area and after digitizing of 
these radiographs, dose distributions were calculated (Figs. 
1 and 2). The isodose best encompassing the target area was 
chosen to calculate the actual application time using the 
activity of the available iridium wire. 
The number of catheters used varied from two to five 
(two: n = 11; three: n = 38; four: IZ = 16; five: IZ = 1). 
The mean total length of iridium per patient was 14 cm 
(range 7 to 27 cm). 
According to the protocol, 10.5 Gy EBRT was applied in 
three patients, in one patient followed by 60 Gy IRT, as 
planned. The two other patients, however, did not receive 
the full course (60 Gy) of IRT; in one patient interstitial 
radiation was terminated after 30 Gy because of unsatisfac- 
tory dose distribution, whereas in the other patient we 
decided to stop IRT after 37.2 Gy because lymphnodes, 
removed prior to insertion of the catheters, appeared to 
contain metastases at definitive pathological examination. 
In both cases, additional courses of 30 and 40 Gy EBRT 
were applied, respectively. 
Following 40 Gy EBRT (in one case 42 Gy), as pre- 
scribed by the protocol, an intended IRT dose of 30 Gy was 
applied in 55 patients, 4 patients received a dose of 35 Gy 
and 2 patients received 24 and 32.5 Gy, respectively. Be- 
cause of postoperative mental distress and confusion, IRT 
was terminated after 26.4 and 16.6 Gy in 2 patients; in the 
latter case, an additional EBRT dose of 12 Gy was applied. 
Sequence and doses of EBRT and IRT are summarized in 
Table 3. 
Optimization of dose distributions was considered neces- 
sary in 11 implants (17%); in 6 implants iridium wires of 
Fig. 1. Anterior-posterior photograph after insertion of catheters 
for IRT. Metal guidewires have been inserted at one end, whereas 
dummy sources with alternating pieces of lead and nylon with a 
length of 1 cm have been inserted from the other side. 
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Fig. 2. Example of an isodose pattern in the central plane perpendicular to the iridium wires; the plane chosen and the 
position of the wires are shown on the right side of the figure. 
different activities were used, in 1 the application time of 
one wire was increased and, finally, in 4 patients PDR was 
used. 
In 62 patients, iridium wires were used: the mean dose 
rate was .58 Gy/h (range: .29-.96). The remaining four 
patients were treated with PDR, using a single iridium 
source: a fraction of 1 Gy was given every 3 h up to a total 
IRT dose of 30 Gy in three patients, whereas the fourth 
patient received 2 Gy fractions every 6 h up to 24 Gy. 
Table 3. Sequence and doses of external beam (EBRT) and 
interstitial radiation (IRT) 
Dose (Gy) 
EBRT IRT 
10.5 60 
10.5 30 
10.5 37.2 
40 30 
40 35 
40 24 
40 32.5 
42 30 
40 26.4 
40 16.6 
EBRT 
30 
40 
12 
No. of patients 
1 
1 
1 
54 
4 
1 
1 
1 
1 
1 
66 
The application time in the one patient who received 60 
Gy IRT was 110.2 h. The mean application time in the other 
65 patients was 56.2 h (range 31.2-104). 
IRT was started within 24 h after insertion of the cathe- 
ters. Depending on the availability of the afterloading ma- 
chine, the catheters were loaded with iridium remotely in 33 
cases, whereas in the other half of the patients they were 
loaded manually. 
After completion of the calculated application time 
the iridium was retracted, the catheters were removed 
and, subsequently, the patient was transported to the 
department at the hospital of the referring urologist for 
further postoperative care and recovery. The time of 
discharge depended on the policy of each department. 
The median hospitalization time was I7 days (range: 8 to 
70 days). 
Patients were seen regularly for follow-up thereafter, 
mostly during joint clinics, cystoscopies and urine cytol- 
ogy being performed routinely. Follow-up from the start 
of EBRT ranged from 5 to 78 months (median: 26 
months). 
Statistical methods 
Data analysis has been primarily descriptive. A formal 
analysis of prognostic factors for bladder relapse was not 
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Table 4. Characteristics of the seven patients with a bladder relapse 
EBRT Partial Lymphnode 
Initial dose cystectomy dissection IRT dose Interval* Distant 
T-category (gy) (pT-category) (pN-category) (k?Y) rT-category (months) Therapy metastases Status 
T2 
T2 
T2 
T2 
T2 
T2 
T2 
40 n.p. 
40 n.p. 
40 pT1 
40 n.p. 
40 n.p. 
40 n.p. 
40 PTO 
PNO 
n.p. 
PNO 
PNO 
n.p. 
PNO 
PNO 
35 rT1 11 
30 rT1 8 
30 rT1 5 
24 rT1 6 
30 rT3a 14 
30 rT3b 6 
3.5 rT4 11 
cystectomy 
(PTO) 
cystectomy 
Wis) 
intravesical 
immunotherapy 
none 
systemic 
chemotherapy 
none 
ureter deviation 
no alive 
(59m,NED) 
subsequent dead 
subsequent dead 
concurrent dead 
concurrent dead 
concurrent dead 
no dead 
n.p. = not performed; NED = no evidence of disease. 
* Interval between start of treatment and diagnosis of bladder relapse. 
feasible due to the small number of bladder relapses (n = 7) 
in this study. Survival curves were calculated by using the 
method of Kaplan and Meier. 
RESULTS 
Bladder relapse 
In seven patients (1 l%, all T2 tumors) a bladder re- 
lapse developed. In five cases the tumor recurred at the 
original tumor site, in one a relapse was found elsewhere 
in the bladder, whereas in the remaining patient recurrent 
tumor was located in and outside the area of the primary. 
Four recurrent tumors invaded the lamina propria (rTl), 
in one tumor deep muscle infiltration was found (rT3a), 
one tumor invaded the perivesical fat (rT3b), and in one 
case the tumor was fixed to the pelvic wall (rT4). Cys- 
tectomy was performed in two patients with a rT1 relapse 
(pathological category pT0 and pTis); one of them re- 
mained disease free (59 months at the moment of data 
collection), the other died of distant metastases later on. 
The patient with rT4 disease underwent a palliative de- 
viation of the ureters and died of local recurrence. One 
patient was treated with intravesical BCG instillations for 
1.0 - 
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Fig. 3. Probability of remaining bladder relapse free, Kaplan- 
Meier curve. 
a multiple rT1 process but died eventually of a fixed local 
recurrence and distant metastases. In the remaining three 
patients (rT1: n = 1; rT3a: n = 1; rT3b: n = l), the 
bladder relapse was found together with distant disease; 
only one patient received systemic chemotherapy; all 
three patients died. 
One patient had a TUR for a papillary transitional cell 
carcinoma, possibly with stroma infiltration, in the urethra; 
this is not considered as bladder relapse. Characteristics of 
the patients with a bladder relapse are given in Table 4. 
The cumulative chance of remaining bladder relapse free 
at 5 years is 88% (Fig. 3). 
Distant metastases 
Metastases developed in 16 patients (24%). In five cases 
metastases occurred following (n = 2) or concomitant with 
(n = 3) a bladder relapse; the remaining 11 patients with 
distant metastases did not develop a bladder relapse. Ten 
patients did not receive any further antitumor therapy, in 4 
patients systemic chemotherapy was given, 1 patient under- 
went palliative EBRT to penis and scrotum, and in 1 patient 
a palliative resection of a part of the small intestine was 
performed. All 16 patients eventually died. 
The cumulative chance of remaining distant metastases 
free at 5 years is 66% (Fig. 4). 
Survival 
During the observation period 25 patients died. The cause 
of death was bladder cancer in 17 patients, whereas 3 
patients died of a second primary (lung, stomach, prostate), 
and 5 of nonmalignant diseases. 
The cumulative 5-year overall and bladder and distant 
relapse free survival rates are 48% and 69%, respectively 
(Fig. 5). 
Complications 
Acute toxicity. EBRT caused a raise in urination fre- 
quency to once every hour or more often (RTOG Grade 3) 
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Fig. 4. Probability of remaining distant metastases free, Kaplan- 
Meier curve. 
in only 9 patients (14%). No serious (i.e., RTOG Grade 3 or 
more) bowel/rectum or skin toxicity has been recorded. 
In 30 cases (45%) no complications developed as a result 
of the operation or IRT. All acute toxicity of EBRT and 
surgeryART is given in Table 5. 
A persisting vesicocutaneous fistula (“delayed wound 
healing” in Table 5) made surgical correction necessary in 
two patients and a wound toilet had to be performed in 
another one. 
In two of the six patients with mental distress and/or 
confusion, IRT had to be terminated before the calculated 
application time had been completed, whereas in one patient 
a short interruption of IRT was necessary. 
No patients experienced a lethal complication. 
Late toxicity. RTOG Grade 3 bladder toxicity (frequency 
once every hour or more) developed in one patient (2%). No 
serious (i.e., RTOG Grade 3 or more) late bowel or rectum 
toxicity has been recorded. 
During follow-up cystoscopies, necrosis was seen in the 
interstitially irradiated area of the bladder in nine patients 
(14%); this necrosis, however, caused symptoms (increased 
frequency and/or dysurea) in only two cases. The mean 
1.0 - 
.8 - 
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Table 5. Acute toxicity 
No. of Percentage 
RTOG patients (%) 
EBRT Bladder 
Rectum 
Skin 
Surgery/IRT Urinary infection 
Delayed wound 
healing 
Mental distress 
andfor 
confusion 
Cardiovascular 
Pulmonary 
Sepsis 
Subileus 
Other 
Grade 0 
Grade 1 
Grade 2 
Grade 3 
Grade 0 
Grade 1 
Grade 2 
Grade 0 
Grade 1 
Grade 2 
26 (39) 
26 (39) 
5 (8) 
9 (14) 
18 (27) 
38 (58) 
10 (15) 
63 (95) 
2 (3) 
1 (21 
10 (15) 
17 
6 (9) 
5 (8) 
6 (9) 
1 (2) 
1 (2) 
10 (15) 
(26) 
period between IRT and the development of necrosis was 10 
months (range 2-19). 
In 13 patients (20%) incrustations in the IRT area of the 
bladder were noticed, causing complaints in one patient. 
Patients developing necrosis appeared to have a higher 
chance of incrustations than those in whom necrosis did not 
occur (44 vs. 14%, p = 0.05). 
Finally, telangiectasia occurred in 15 patients (23%), 
causing intermittent hematuria (less than once a month) in 
only one patient. 
Late bladder toxicity is summarized in Table 6. 
DISCUSSION 
Nowadays, IRT using the iridium afterloading tech- 
nique aiming at organ preservation in bladder cancer 
patients, seems to be applied almost exclusively in Dutch 
and French centers (3, 31, 34, 37), although reports on 
two very small series have emerged from American cen- 
ters as well (20, 40). Following the paper of Gros et al. 
(19) on the use of afterloading iridium wires instead of 
directly inserted radioactive material, French centers 
Table 6. Late bladder toxicity 
No. of patients Percentage (%) 
Subjective* Grade 0 61 92 
Grade 1 1 2 
Grade 2 3 5 
Grade 3 1 2 
Objective Necrosis 9 14 
Incrustations 13 20 
Telangiectasia 15 23 
Fig. 5. Actuarial overall and bladder and distant relapse free 
survival, Kaplan-Meier curves. * RTOG grading. 
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adopted this technique soon afterwards (6, 14), whereas 
Dutch centers did not change their IRT technique until 
the last 10 years (3, 31, 53). In a nonrandomized study we 
did not detect a difference in the complication rate be- 
tween a group of patients in whom caesium needles were 
used for IRT and a group of patients in whom the iridium 
afterloading technique was applied in the same period of 
time (53). 
Compared to a not yet completely published series of 183 
patients with muscle invasive bladder cancer, treated in our 
center by EBRT and radium or caesium needle implantation 
from 1981 until 1989 (54), the present series shows an 
improved bladder tumor control rate (88 vs. 70%) and 
similar survival rates. 
Selection criteria appear to be quite similar in four 
recently published series on IRT using iridium in bladder 
cancer patients, in comparison to this report (3, 31, 34, 
37). However, in the French centers a tumor biopsy was 
performed routinely prior to definitive therapy, and oc- 
casionally a tumor resection, i.e., almost all patients 
underwent a partial cystectomy or a resection of the 
tumor immediately before insertion of the catheters for 
IRT; in the series of Rozan et al., apparently multiple 
mucosa biopsies were performed as well, to exclude 
patients with multiple tumors (34, 37). In the Dutch 
centers, a TUR of visible tumor was performed routinely 
without random biopsies; a partial cystectomy was only 
performed to facilitate IRT in some patients (8-24%) 
[present series, (3,31)]. In our series, 6 out of 16 patients 
undergoing a partial cystectomy (37%) appeared to have 
a pT3 tumor, whereas their initial tumor was classified as 
T2, demonstrating the inaccuracy and risk of understag- 
ing in clinical staging of bladder cancer. Rozan et al. 
(37), as well as Pernot et al. (34) used a low dose of 
EBRT (11 Gy and 10.5 Gy, respectively) and a high dose 
of IRT (50 Gy), although Pernot eE al. decreased the IRT 
dose to 30 Gy in case of large pT2 and pT3 tumors, 
adding postoperative EBRT. In the series of Batter- 
mann (3) and of Moonen et al. (31), 30 Gy EBRT and 
40 Gy IRT were applied, whereas in the present series 
the majority of patients received 40 Gy EBRT and 
30 Gy IRT. 
In 18% of the patients with a pT2 or pT3a tumor (n = 92) 
in the series of Rozan et al. (37), a bladder relapse was 
observed. In the series of Battermann (3) (mainly T2 pa- 
tients), 21% developed a bladder relapse, whereas in the 
series of Moonen et al. (3 1) in 2 1% of the T2 cases a 
bladder relapse occurred. 
The probability of remaining bladder relapse free at 5 
years in pT2 tumors in the series of Pernot et al. (34) was 
64%. The observed bladder relapse rate (11%) and the 
cumulative chance of remaining bladder relapse free at 5 
years (88%) in our series compare favorably to these data. 
The bladder was preserved in 98% of the surviving patients 
in our series, whereas in 84% of the patients who died 
during the observation period bladder functioning was re- 
tained. 
Half the percentage of the bladder relapses in the series 
of Moonen et al. (31) and 71% of the bladder relapses in 
our series occurred at the original tumor site, whereas 
tumor recurrence was actually local in only 29% of the 
relapses in the pT2 and pT3 cases of Rozan et al. (37). A 
possible explanation for this difference might be that by 
using a higher dose of EBRT in the Dutch centers a more 
homogeneous dose is applied to the whole bladder mu- 
cosa, thereby possibly killing (pre)malignant cells out- 
side the tumor area. One would expect that by excluding 
patients with multiple tumors detected by random biop- 
sies, as reported by Rozan et al. (37), the number of 
relapses outside the original tumor area will be low. 
However, according to the abovementioned percentages 
with respect to site of bladder relapses, this seems not to 
be the case. 
In our series, three of the seven patients with a bladder 
relapse (43%) had concurrent distant metastases. Moonen et 
al. (31) report concurrent metastases in four of the six 
patients with a bladder relapse (66%), whereas in the series 
of Rozan et al. (37) this is 28%. In both Dutch series, 
bladder relapses developed in patients with T2 tumors only, 
whereas in the French series 42% of the bladder relapses 
occurred in patients treated for a pT1 tumor, which might 
explain the difference in the development of concurrent 
metastases. 
Three of the 42 patients (7%) in our series who under- 
went a lymphnode dissection appeared to have nodal 
metastases; Rozan et al. (37) report 2.5% node metasta- 
ses, whereas Pernot et al. (34) discovered nodal metas- 
tases in 25% of the patients with “larger and more 
infiltrating tumors’ ’ . Unless the treatment plan will be 
changed, or adjuvant systemic chemotherapy will be of- 
fered in case of positive nodes, a lymphadenectomy does 
not seem to be warranted in patients with bladder cancer 
selected for IRT. 
Although Gros et al. mentioned the possibility of opti- 
mization of the dose distribution by “playing” with the 
activity or the application time of different iridium wires 
within one implant as early as 1969 (19), so far this has not 
been reported in any other article on IRT in bladder cancer. 
We optimized the dose distribution in 11 patients by using 
different activities of iridium, different applications times, 
or by applying PDR; however, we were not able to prove a 
positive effect. 
Distant metastases developed in 22% of our patients, 
whereas 15% (mainly T2 cases) and 18% (T2 cases only) 
were reported by Battermann (3) and by Moonen et al. (3 l), 
respectively. Due to a relatively large number of intercur- 
rent deaths the actuarial 5-year overall survival was only 
48% in our patients. The actuarial 5-year bladder and distant 
relapse free survival was 69%, in accordance with the data 
from the French centers [Pemot er al.: pT2 cases: 76%; pT3 
cases: 72% (34); Rozan et al.: pT2 cases: 80.9%; pT3 cases: 
62.2% (37)]. 
Because different definitions are used, a comparison of 
acute and late toxicity in the different papers is hardly 
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possible. In our opinion, the three patients in our series in 
whom a second operation was necessary due to wound 
healing problems represent the most serious toxicity of 
surgery followed by IRT. Lethal complications were not 
encountered in Rotterdam, although three other article re- 
port an occurrence of 2-3% (3, 34, 37). 
Late complications such as ulceration/necrosis and in- 
crustations/bladder stone formation are not uncommon, but 
asymptomatic and temporary in the majority of cases 
[present series, (3, 31, 34)]. 
We were not able to detect any influence of IRT dose, 
dose rate, application time, and length of iridium wires on 
the development of complications. Pemot er al. (34) report 
that serious toxicity in 5 patients was related to dose rate 
(62 Gylh), surface area, spacing of the wires and start of 
IRT on the day following the operation. French centers 
advise loading of the catheters a week after surgery (34, 37). 
In our experience, a mean dose rate of 58 Gy/h and start of 
IRT within 24 h after surgery are not related to serious 
toxicity, although one should keep in mind that the IRT dose 
applied in our center is generally lower than that reported in 
the French series. 
Because randomized studies have not been performed 
and because IRT in bladder cancer is applied in a selected 
group of patients, a proper comparison with the results of 
other treatment modalities is not possible. 
In many centers, patients with muscle invasive bladder 
cancer undergo a radical cystectomy; as a result, the possi- 
bility of natural voiding is sacrificed. Recent series (18, 29, 
39, 42, 56) reported 5-year overall survival rates varying 
from 23-82% after radical cystectomy. Radical EBRT of- 
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fers the possibility of preserving the bladder, but local 
relapse rates of 35-61 and 48% to >70% have been re- 
ported for T2 and T3 tumors, respectively, whereas the 
overall 5-year survival varies from lo-64% (4, 11, 13, 16, 
17, 28, 36). 
The alternating or concomitant application of systemic 
chemotherapy and radical EBRT has been reported to result 
in high complete response rates with bladder preservation in 
38-58% of the patients (9, 33). 
Finally, in many studies neoadjuvant chemotherapy and 
EBRT with concomitant chemotherapy have been used to 
select patients for bladder preservation, which is eventually 
achieved in up to 70% of the cases (1, 15, 25, 41, 50). 
It remains unclear which patients should be selected for 
any of the latter two therapies mentioned, with the possi- 
bility of bladder preservation, whereas selection criteria for 
IRT are well defined. 
CONCLUSION 
Interstitial radiation preceded by transurethral resection 
and external beam radiotherapy in a selected group of 
patients with muscle invasive bladder cancer yields an ex- 
cellent bladder tumor control rate, with a very high proba- 
bility of bladder preservation. Survival is mainly dependent 
on the development of distant metastases. Serious acute and 
late toxicity is rare. A close cooperation between urologist 
and radiation oncologist is an essential condition for achiev- 
ing these results, as well as the availability of modem 
brachytherapy facilities. 
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